Sofosbuvir Based Regimens in the Treatment of Chronic Hepatitis C with Compensated Liver Cirrhosis in Community Care Setting
Table 2
Demographic and clinical characteristics of patients at baseline by treatment response.
Characteristics
All patients (N =112)
Treatment Response
Univariate Analysis p-value
Multivariate Analysis p-value
SVR
No SVR
(n =101)
(n =11)
Age (years)
60.7 (28-82)
60.7 (28-82)
60.0 (45-67)
0.797
NA
Age group
0.747
NA
< 65
74 (66.1)
66 (65.3)
8 (72.7)
≥ 65
38 (33.9)
35 (34.7)
3 (27.3)
Sex
0.194
NA
Male
67 (59.8)
58 (57.4)
9 (81.8)
Female
45 (40.2)
43 (42.6)
2 (18.2)
BMI (Kg/m2)
29.0 (18.5-47.0)
29.4 (19.0-47.0)
25.8 (18.5-32.5)
0.050
0.085
BMI (Kg/m2)
0.353
NA
< 30
65 (58.0)
57 (56.4)
8 (72.7)
≥ 30
47 (42.0)
44 (43.6)
3 (27.3)
HCV Genotype
0.150
NA
1a
66 (58.9)
57 (56.4)
9 (81.8)
1b
34 (30.4)
34 (33.7)
0
2
5 (4.5)
4 (4.0)
1 (9.1)
3
3 (2.7)
3 (3.0)
0
4
4 (3.6)
3 (3.0)
1 (9.1)
HCV RNA (IU/mL)
1.000
NA
< 800,000
31 (27.7)
28 (27.7)
3 (27.3)
≥ 800,000
81 (72.3)
73 (72.3)
8 (72.7)
Prior treatment
1.000
NA
Naïve
86 (76.8)
77 (76.2)
9 (81.8)
Experienced
26 (23.2)
24 (23.8)
2 (18.2)
Comorbidities
Diabetes
35 (31.3)
31 (30.7)
4 (36.4)
0.738
NA
Hypertension
51 (45.5)
46 (45.5)
5 (45.5)
0.995
NA
Coronary artery disease
12 (10.7)
12 (11.9)
0
0.604
NA
Kidney disease
9 (8.0)
8 (7.9)
1 (9.1)
1.000
NA
Chronic anemia
5 (4.5)
4 (4.0)
1 (9.1)
0.410
NA
HIV Seropositive
24 (21.4)
20 (19.8)
4 (36.4)
0.245
NA
MELD score
0.060
NA
< 10
62 (55.4)
59 (58.4)
3 (27.3)
≥ 10
50 (44.6)
42 (41.6)
8 (72.7)
Laboratory tests
Hemoglobin (g/dL)
13.4 (9.2-17.5)
13.3 (9.2-17.5)
13.9 (11.6-15.9)
0.276
NA
Platelets (x1000/mL)
140.7 (23-316)
146.4 (23-316)
88.6 (43-177)
0.002
0.020
Albumin (g/dL)
3.5 (1.3-4.7)
3.6 (1.3-4.7)
3.2 (2.2-4.1)
0.042
0.873
AST (IU/L)
82.3 (16-210)
81.6 (16-198)
88.7 (42-210)
0.585
NA
ALT (IU/L)
77.8 (12-264)
77.2 (12-204)
83.9 (27-264)
0.666
NA
Bilirubin (mg/dL)
1.2 (0.3-4.9)
1.1 (0.3-3.9)
1.6 (0.8-4.9)
0.043
0.821
Data are presented as mean (range) or number (percentage). Only variables with the p-value < 0.05 in univariate analysis were assessed. BMI, body mass index; HCV, hepatitis C virus; RNA, ribonucleic acid; APRI, AST-to-platelet ratio index; MELD, model for end-stage liver disease; AST, aspartate transaminase; and ALT, alanine transaminase.
